These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 8944008)

  • 1. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
    Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G
    J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.
    Ciardiello F; Tortora G
    Clin Cancer Res; 1998 Apr; 4(4):821-8. PubMed ID: 9563874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
    J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells.
    Ciardiello F; Damiano V; Bianco C; di Isernia G; Ruggiero A; Caraglia M; Tagliaferri P; Baselga J; Mendelsohn J; Bianco AR
    Clin Cancer Res; 1995 Feb; 1(2):161-7. PubMed ID: 9815969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
    Normanno N; Tortora G; De Luca A; Pomatico G; Casamassimi A; Agrawal S; Mendelsohn J; Bianco AR; Ciardiello F
    Oncol Rep; 1999; 6(5):1105-9. PubMed ID: 10425310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer.
    Bianco C; Tortora G; Baldassarre G; Caputo R; Fontanini G; Chinè S; Bianco AR; Ciardiello F
    Clin Cancer Res; 1997 Mar; 3(3):439-48. PubMed ID: 9815703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidermal growth factor receptor as a target for cancer therapy.
    Mendelsohn J
    Endocr Relat Cancer; 2001 Mar; 8(1):3-9. PubMed ID: 11350723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human pancreatic cancer cell (MIA PaCa-2) growth by cholera toxin and 8-chloro-cAMP in vitro.
    Ohmura E; Wakai K; Isozaki O; Murakami H; Onoda N; Emoto N; Shizume K; Tsushima T; Demura H; Robins RK
    Br J Cancer; 1993 Feb; 67(2):279-83. PubMed ID: 8381655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
    Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
    J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.